Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Devyser Diagnostics, Audiocast, Q4'25

By Inderes2/12/2026, 8:00 AM
Devyser Diagnostics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jan Wahlström
00:02 - 06:14

Good day, and welcome to the Devyser Q4 2025 Earnings Call. I'm Jan Wahlström, CEO of Devyser, and would like to thank everyone for joining our call today. On the call today, in addition to myself, we have our CFO Sabina Berlin and our CEO, Theis Kipling. I will start with a short summary of our quarterly results, and then recap our recent activities that resulted in a record profitable quarter, as well as a record sales quarter. I will give you an update on the recent product launches and present some additional highlights from the quarter, before handing over to Sabina for a more detailed review of our financial results in Q4 2025, and then to Theis for an update on our recent commercial activities. As headlines, I would say that we have started a new journey in the beginning of this year and focused the company towards profitable growth for the full year. We now deliver EBIT profitability and we will continue to focus on costs at the same time as we drive growth at a high pace. Looking at the fourth quarter highlights, we are turning the company around on a path to profitability. We had another record quarter based on revenue, with 72 million in sales, representing a growth of 20% compared to Q4 last year. Growth in reported currency was lower than in local currencies due to currency headwinds. Gross margins came in at 79%. It's a disappointment, and we will continue to work on improving the margins in 2026. What we are most satisfied with in the report is that EBIT came in at 18 million, delivering 25% EBIT margin in the last quarter. Last year, EBIT was -3.7 million. Our cash position is now 77.5 MSEK. If I then move over to year-to-date financials, sales year-to-date reached 250.5 million, up 15.5% overall, or 20.2% in local currencies. Gross margin exceeded our target of 80%. The February reorganization we did supported ongoing improvements to costs and sustainable growth, giving us an EBIT for the year of 10.1 million compared to last year's -62 million. In the second half. We have maintained strong growth. We have controlled costs and had new product launches, as well as signed recent agreements with partners like Quest and Illumina. This quarter, EBIT exceeded 20%. Our collaboration with Thermo Fisher Scientific remains robust, showing positive trends in both sales and lead development. And we've also seen in Italy, our largest market, achieving double-digit growth and continuing to gain market share. As you might have seen, yesterday we announced that Devyser has entered into an agreement to acquire 100% of the shares in CyberGene AB, a Swedish company within the LevelBio AB Group. The acquisition is subject to Devyser obtaining customary regulatory clearance, and the purchase price was 12 million, based on an enterprise value of 8.9 million. CyberGene AB is a Stockholm-based diagnostic company and has operated in the same markets as Devyser for many years, providing Devyser with an in-depth knowledge of the market's products and customers. CyberGene AB has demonstrated steady growth, driven by a strong product offering and consistent market expansion, and will contribute positively to our gross profit as well as our gross margin. The transaction is scheduled for completion on April 1st of this year, and I expect transition and integration to be a smooth process. We then move over to product launches in Q4 and for the full year. We introduced CFTR IVDR, our most significant internal project so far. Not only did we secure IVDR approval for an important product, but we also established a solid foundation to replicate this process for several other products. The products that we launched in Q2, genomic blood typing and HLA loss have performed well in the market, and Theis will provide further detail on this later in the call. Finally, on more highlights, I would like to add a couple of other activities from the quarter. Work continues on the MolDx evaluation for our post-transplant test in the US. We got feedback on our application at the end of October, and they requested additional supporting data. This required more clinical data that we have now gathered since November, and we are now analyzing those clinical samples. We expect to be able to file a new application to MolDx after the summer. At the same time, we continue to work on our FDA project in transplantation, and we have very positive development in this work. We now have six sites in the US where we gather patient data, and we'll continue to do so during 2026 and 2027 to be able to file in 2028 if everything develops in a positive way. And with that, I would like to hand over to Sabina to share more details on our financial results for Q4 2025.

Sabina Berlin
06:16 - 09:26

Thank you Jan. I will then continue with some more details on the financials for Q4. Revenue for the period October to December. As Jan said, came in at 72 million compared to the 64 million in the same quarter of last year. That amounts to a quarter-over-quarter growth of 12%, equaling 21% in local currency. This quarter has been heavily impacted by FX, as has the past year, but we could still present our strongest quarter ever in this report. Our sales growth continues to be clear in the rolling 12 curve. Q2 and Q4 quarters tend to be stronger based on our distributor purchasing patterns. So a 12-month rolling view is always interesting and relevant to highlight for us. We have a stable underlying growth that is very clear when we work with our growth numbers in local currency. EMEA had a good Q4 with 20% growth, with most of our direct markets contributing strongly. Together with the Q4 order from Thermo. The Americas doubled in the full year, combining revenue from partner sales, our direct sales, and Devyser Genomic Laboratories. The region is continuing to, step by step, make up a larger portion of our business. The lower sales number in Q4 compared to last year is due to Thermo ordering their year-end inventory to Europe instead of us, so that is a phasing issue only, and APAC continues to be an interesting future market with high potential, but still less of a focus for us in the short term. Q4 saw direct sales grow by 19% during the quarter and 11% during the full year. Distributor sales had a strong Q4 both this year and last year, and we saw healthy annual growth during the full year. Gross margin in the isolated quarter was 79.5%, supported by the large sales growth, but also impacted by a lower than average number of hours booked into inventory due to production scheduling. Year to date was 80.6% above our financial target. Our EBIT for the quarter was 18 million SEK positive, taking the full year to EBIT positive at 10 million SEK. The strong EBIT was driven by a combination of the strong revenue in the quarter and the lowered cost run rate driven by the right-sizing of cost structure that we started a year ago and have continued to maintain since. I see this as a strong indication of our ability to run Devyser as a long-term, sustainable, cash-flow positive business. We closed the quarter with 77 million in cash. The Thermo order we received in Q4 came in quite late in the quarter, and we received payment on this side of the new year. Cash flow from operating activity was 12 million positive for the quarter and 8 million for the full year. And with that, I hand over to Theis.

Theis Kipling
09:27 - 17:58

Thank you, Sabina, and good morning from Italy. I'm very pleased to share several promising highlights from our strong Q4, which was another record quarter on several fronts. When I joined Devyser four years ago, we reported full year 2021 revenues of roughly 90 million SEK. And we really didn't have much of a commercial organization, nor a platform for growth. Looking back today, I see a company that is completely transformed and is recognized by our customers, competitors, and strategic partners as a strong and serious company that they really were keeping a close eye on during 2025. We delivered many breakthroughs, and not least by delivering on our EBIT financial target during the past quarter. We also made considerable progress on our new customer lead generation, which drove a large number of new customers recently onboarded, with whom we are diligently working on supporting them to reach their full potential. Our growth in North America continued and in the past year, doubled versus 2024, driven by a consistent, incremental onboarding of new customers, as well as sustained growth. Growth in Europe is also continuing as per plan with several highlights. And to repeat what we also said in our Q3 earnings call, we have some very strong fundamentals in Devyser. We have a wide, strong workflow, efficient product portfolio. We have a very strong regulatory capacity and are leading in Europe when it comes to IVDR. This new regulation is a structural change to the market and we are very strongly positioned to exploit this. We have multiple strong growth drivers, including penetration across the largest markets of the world, spearheaded by us with our Clear lab, the FDA program, and naturally, the partnership with Thermo Fisher and now also Illumina. On January 28th, we announced that Devyser is a systems integrator with Illumina as we entered into a collaboration framework agreement. Illumina is by far the market leader when it comes to DNA sequencing. And despite the entry of several new instrument manufacturers, I'm confident that they will remain a market leader for decades ahead. We have all our NGS products validated on the Illumina MiSeq platform, which has significant instrument coverage across the globe. This is important for Devyser since this lowers the entry barriers into new accounts. The new agreement enables Devyser to place their newly launched MiSeq i100 product family in the markets that we serve, and Devyser was carefully chosen as a partner to Illumina for several reasons. But one of the key reasons is our strong regulatory position when it comes to IVDR in Europe. The old Illumina MiSeq platform is being discontinued and will be replaced in the coming years with the new MiSeq i100 platform. This creates the need to replace the old platform with the new platform. With the ongoing implementation of IVDR, it is expected to be a strong growth opportunity for Devyser to leverage, and thus we do expect to be placing a considerable number of instruments in the coming years. The way this works is Devyser buys the instrument and consumables from Illumina and places them under a multi-year reagent rental agreement with the customers. The customer benefit is that they don't need to allocate a significant amount of upfront capital for the instrument acquisition, but instead can pay through a higher price on the Devyser products in a similar manner as it's seen with most leasing arrangements today in other markets. The benefits for Devyser are the increased revenues driven by the higher product prices, which will drive up margins and, not least, increase customer stickiness. This is a proven model in many markets and is the most commonly used business model in the pathology segment, which is the segment that I came from at Agilent. And I'm confident that this will be a successful model also for Devyser. Moving on to an update on our partnership with Thermo Fisher. Q4 was, as expected, a very strong quarter, and we're pleased to see continued growth and onboarding of new customers. As mentioned earlier, we do expect lumpiness, but also expect it to gradually level out over the years. Our transplantation business continues to shape our company and will remain a significant potential and growth driver for the company's future. We have some very exciting milestones ahead of us this year, both when it comes to MolDx and the FDA program, and we're very pleased with the consistent customer onboarding pace that we are seeing from Thermo Fisher. North America had another strong quarter and doubled revenues on a full-year basis versus 2024. We now have both Quest Diagnostics live in the US with our RHD test. And as of January this year, Canadian Blood Services went live with the tests in Canada. We don't expect an immediate massive uptake on either of them, but rather to see consistent growth over the coming years. It takes time to build such a market. The collaboration with Cyted is developing well and is expected to grow further during the coming years. Jan and I visited Cyted last week in Cambridge, and both sides are pleased with the collaboration and the outlook. It's definitely an exciting time also for Cyted, with a unique product offering that they are taking to the US patients. Moving on to Europe. I'm pleased to share that Italy continued to deliver well and show double-digit growth in a market where we already have a significant market share position across Europe. The IVDR regulation is being adopted and we are seeing consistently increasing demand, which is expected to further accelerate as we get closer to the full implementation deadline. Recently, we attended the Festival of Genomics conference in London, where a new customer of ours from Oslo in Norway presented data for cystic fibrosis tests and clearly underlined the workflow and regulatory status of the product, which, as he said in his own words, enabled their laboratory to reduce the turnaround time from two days to just one hour with the IVDR status. It's an easy onboarding of new customers, which, combined with our new instrument placement ability, created a lot of positive interest in our booth. While having been direct for more than a year already. We have kept the relation with our distributors in Spain. And we are cautiously proceeding. We've been cautiously transitioning from a distributor-managed approach to directly managing the customers, which we are now fully taking over as of January 1st of this year. The Spanish market is very similar to our Italian market, and hence we will be applying the same way of working as in Italy. Many of the customers that we have in Spain have historically relied on our fragment analysis portfolio, which in recent years has gradually expanded to include our NGS portfolio. However, limited by how Illumina has had its channel partnership structure in the Spanish market. With our new agreement with Illumina, we expect that we can open up new pathways to win over new customers in Spain, which is equally a very significant market as in Italy, and aiming to repeat the same success story as we have achieved in Italy. With that, I'll hand it back over to you.

Jan Wahlström
17:59 - 18:56

Thank you, Jan and Sabina. Devyser has delivered. We have delivered our best quarter yet with EBIT exceeding 20%, demonstrating the effectiveness of our strategy and this year's effort. We introduced new products and solutions to the market, including the HLA loss in Q2 and CFTR IVDR in Q4. And we're progressing towards our long-term goals by investing in innovation and forming collaborations, most recently, the great collaboration that I talked about with Illumina. Our focus remains on continuous improvement and increased profitability alongside strong top-line growth. We're moving towards positive cash flow, and with this report, our trajectory has definitely improved. With that, I would like to open to questions.

Operator
19:00 - 19:20

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.

Ulrich Trattner
19:22 - 20:05

Thank you very much. And a few questions on my end. Let's start with the impressive cost reduction achieved throughout 2025, and the level we are at in the second half of the year. In absolute terms, how comfortable are you that you can maintain this level as the company grows? Obviously you have new product launches. You're advancing forward with FDA trials, MolDx reimbursements. So how much should we extrapolate this opex level that we are at currently?

Jan Wahlström
20:07 - 21:00

Thank you for the question. As you say, we have done quite a significant job on the cost side for 2025 and put ourselves in a position where I see that we have a good structure when it comes to cost for the type of business we run. I believe that we can continue staying on a similar cost level going forward. Of course, in the longer run, when our growth continues to improve, we will at some point need to start investing into the commercial organization. But that's not something that we see in the coming quarters. We see that we have a good fundament that we can grow the business on.

Ulrich Trattner
21:03 - 21:52

That's great. And building into your investments here. A few questions on that, please. First, this acquisition that you announced late yesterday, my impression has been that mainly infertility has been part of your portfolio historically, but not potentially the most prioritized segment. Is this a new vertical that you have identified that you want to expand within? If you can give us the rationale, and I had a look late last night and it looked like a PCR test and not an NGS test. So, how does this fit into your transitioning from PCR to NGS portfolios?

Jan Wahlström
21:53 - 21:55

Thank you Ulrich. I leave that question to Theis.

Theis Kipling
21:56 - 23:20

Yes. Let me answer that one. You're right that this is not a portfolio that is on NGS technology. But we're very happy that it relies on PCR and fragment analysis, which complements our compact and complete and extend product portfolio really, really well. And those products in our portfolio are the longest standing. And we have a very broad coverage. And the way we tactically and strategically will use this and how we value the deal here is that this gives us broader reach because they've been around for several years. They're doing really well as a company. We have been up against in many competitive situations. And we've been watching them with full admiration. So they will actually complement our footprint nicely. As an example, their largest market is France, which is a market that we are quite rapidly penetrating. And that is remaining to be the strategy of Devyser. And that is remaining to be the strategy of Devyser. So this is a future-proofing part of this portfolio and is also helped by the agreement we now have with Illumina, because we believe that there will be an increased adoption coming ahead of us.

Ulrich Trattner
23:23 - 24:05

A few questions on that, please. That's great. This transitions me to my next question regarding the collaboration with Illumina. Based on the face value of what you present, it looks like you will tie up capital by purchasing these systems from Illumina. And from purely a PNL, a financial perspective, it looks like this will initially hamper your margin profile. So just curious on how you will disclose system sales and margins going forward with this new Illumina collaboration.

Sabina Berlin
24:08 - 25:01

And I can take that one. And I understand your concern that this will be weighing down our capital structure, but it will not, as these are long-term leased to a third party, so you will not have an impact on our cash flow. We will not be disclosing margins specifically for this partnership, as we don't do that for any of our partnerships, but we will be sure to keep the market updated on a level where you can feel comfortable as we do, that this is something that's contributing and in no way weighing down our business. So the structure of the customer agreement versus hourly structure is to the benefit of us.

Ulrich Trattner
25:05 - 25:42

We will not be disclosing margins specifically for this partnership, as we don't do that for any of our partnerships, but we will be sure to keep the market updated at a level that assures you, as it does us, that this is something that's contributing and in no way weighing down our business. That's fine. Just also to get some sense or clarity, is it fair to assume that we would estimate limited revenue contribution from the Illumina machines themselves, whereas you would make a higher sort of profit on the reagents? On the actual system that you place, i.e., From a purely accounting perspective, it will be close to a zero-sum game in terms of the actual NGS instruments themselves.

Jan Wahlström
25:42 - 25:43

Do you want to take that one?

Theis Kipling
25:45 - 26:13

Yeah, I can do that. Yeah, I think that's a reasonable assumption. It will obviously drive, as you say, on our individual products, an uplift both in terms of prices and hence also margins. But we're not opening up a new business segment where we will be selling instruments and gaining a lot of margins from this. This is an enabler to accelerate business in general.

Ulrich Trattner
26:15 - 26:57

That sounds fair. We'll ask a last question on my end regarding the US. Obviously, in relative terms, you're growing in absolute terms. It looks like a very minor contribution. You sound forward leaning. You have Quest, you have Thermo Fisher. Should we assume that it would be continuous, very minor in terms of percentage of group sales until you actually have the MolDx reimbursement in place? And what is sort of the near-term triggers that we have beyond MolDx in terms of accelerating American sales.

Jan Wahlström
26:59 - 27:00

Twice for you as well?

Theis Kipling
27:01 - 27:51

Yeah. I think, on the first part of the question, we will see a gradual, continuously upward-going growth curve in the US from the customers that we have just onboarded. And we're continuing quite a number of new customers. So the U.S. is where, when we look in the lead funnel, we currently have the biggest funnel. Right. And the most traction. So, I expect a lot from that in this year and the years ahead. Also, on MolDx, that goes back to Jan's commentary earlier with the timing. And naturally, this will be accelerating growth quite much once we get that positive approval.

Ulrich Trattner
27:55 - 28:08

Great. Is there anything else that would essentially trigger an acceleration in sales beyond the underlying traction that you have in your sales funnel and MolDx?

Theis Kipling
28:10 - 29:25

I would say to comment on that. There's no one trick, right? What you're seeing us do is building out a very strong foundation for a company that has multiple different ways to grow. And we are accelerating all those verticals in a very, very strong way. The partnership with Illumina is the first of its kind. Illumina has never made a pan-European agreement like they have here. So and I think that that is unique. Right. Just from that one, I think we will see us strengthening our position in various markets. We are gaining real market trust. So you can see these strategic partnerships are coming, whether it's Quest, Thermo Fisher, Illumina, or other partners. And that is something I would expect to continue as we are now increasing our credibility in the market. And we are really strengthening the position we have here. So I'm super as always. You know me, I'm always on the bullish side, but I rely on what we have done. More so than words, look at the actions.

Ulrich Trattner
29:26 - 29:46

Yeah, absolutely. It's kind of more aiming towards if you could tease us with the new product launches, more specifically within the transplantation field, expansion into more solid organs here in the near term offering to the US market.

Theis Kipling
29:47 - 30:28

I think we have shared those insights already from the 2024 Capital Markets Day, with the coming indications, moving beyond kidney to also include heart, liver and lung, taking those through IVDR. And there's a pathway also in the US at some point to do that. But in the US, it's initially focusing on kidney for both the MolDx and the FDA application. But again, going back to the Capital Markets Day, there were a number of additional products in the transplantation space that are still being worked on in the R&D department. And it will be quite intriguing once they hit the market.

Ulrich Trattner
30:31 - 30:36

That's great. Thanks for taking my questions and I'll get back into the queue.

Operator
30:43 - 30:47

The next question comes from Ludvig Lundgren from Nordea. The next question comes from Ludvig Lundgren from Nordea.

Ludvig Lundgren
30:49 - 31:08

Yes. Hi. And thank you for taking my questions. So I have two, starting off on the gross margin here. If you can just elaborate a bit more on why it was on the softer side here in the quarter and whether there were some mix effects that were somewhat of a one-off or how we should think about this moving forward.

Sabina Berlin
31:11 - 33:09

Well, I can answer that. And we do have some lumpiness over the year, in individual quarters, in our gross margins, the way our production is structured. And so it's important to always look at gross margin over longer periods, either full year or 12 months rolling. The reason is that our production of diagnostics kits is very much based on how the raw material comes to us. The oligos that make up a majority of the kits. So that can sometimes be needing three times more hours than the previous batch of the same kit, meaning that we're very dependent on how our production is scheduled over the year in terms of bringing hours into inventory. And this is a mix that we are trying to solve still within the IFRS framework. Unfortunately, IFRS bookkeeping is designed for production environments where everything takes the same amount of time every time. So this is not a sort of leakage in our production. But it's very much how scheduling matches the budgeted scheduling that we have. So, yes, this is a weaker quarter. But we also had a very strong quarter a year ago. Looking back. So this is not a concern per se, despite us not being above 80%, but it's something we need to fix to make sure that the market receives much clearer reporting and much more stability over the year. And we're working on it.

Jan Wahlström
33:11 - 33:26

I can just add to that as well. From me, Jan, here, we're working on internal efficiencies in production, and we believe this will improve our gross margin in the year to come.

Ludvig Lundgren
33:31 - 33:57

Well, we're slowing down R&D cash flow but not working speed. Well, we're slowing down R&D cash flow but not working speed. Well, we're slowing down R&D cash flow but not working speed. Very clear. And then jumping over to operating expenses, which was a bit lower than I expected, at least here in the quarter. So maybe starting off on the R&D side, I think gross R&D was around the lowest level for the year. Was there any type of one-offs in here, or is this just you slowing down the R&D investments a bit sequentially?

Sabina Berlin
33:58 - 34:29

Well, we're slowing down R&D cash flow but not working speed. So part of the re-organization that we did last year, we have restructured the R&D department and kept as much of the efficiency as possible while reducing costs. And so there's no specific one-off that reduces the R&D run rate, but rather being at a level that fits our cost base.

Ludvig Lundgren
34:32 - 34:47

Okay, great. And just a follow up on R&D. So capitalization rate was, I guess, a bit higher than usual here with only 2 million in the PNL on the R&D side. Is this something to extrapolate ahead?

Sabina Berlin
34:49 - 35:03

I don't think you ever should look at individual quarters, but the past few quarters have given a pretty reasonable assumption on where our run rate for capitalization will be over the coming period.

Ludvig Lundgren
35:06 - 35:11

So, as part of the re-organization we undertook last year, we have restructured the R&D department and maintained as much efficiency as possible while reducing costs. Who would like to take that? And it really strengthens our total position within aneuploidy and male infertility. Yeah. I'll jump back into the Q&A, thank you.

Sabina Berlin
35:11 - 35:12

So part of the reorg that we did last year, we have restructured the R&D department and kept as much of the efficiency as possible while reducing costs.

Operator
35:17 - 35:22

The next question comes from Phillip Wiberg from Pareto Securities. So, as part of the reorganization that we did last year, we have restructured the R&D department and maintained as much efficiency as possible while reducing costs.

Phillip Wiberg
35:23 - 35:55

Hi. Good morning. I've got a few questions, and I think I'll start with a follow-up on the acquisition that you did here. So I just had a quick look on the product portfolio last night, and it seems to have a very significant overlap with what you already have. So both on what the actual tests are and the technology. I think you touched upon this a little bit, but it's also to get the reach. But can you just talk a little bit about the reasons why you did this acquisition?

Jan Wahlström
35:56 - 35:59

Who wants to take that?

Theis Kipling
35:59 - 37:31

Yes, I can do that. Philip, you're absolutely right. It is quite an overlap with the existing portfolio. But we see that as a strong component to what we just did here. And their products are also quite well ahead and in good place to become IVDR. So that means there's a long horizon for how long these products can remain on the market. And it really strengthens our total position within aneuploidy and male infertility. And we are taking on quite a number of additional accounts, new accounts that we are not in today, which is right on strategy. We want to be maximizing that. And we saw an opportunity here that would accelerate that quite a lot. And then, as I've said before, regarding our strategy, we have a very complementary portfolio in many of these parts with the NGS overlap. Our goal is to achieve a broader share of wallet with these accounts and then gradually help them adopt NGS technologies, which will significantly increase the average selling price. And not only will it increase the stickiness by placing these. For example, now we can place the instruments on five-year contracts. But the fact is that usually these instruments, they sit with the account for a lot longer than the initial contract period. So that's the logic behind the deal.

Phillip Wiberg
37:33 - 37:53

And we are taking on quite a number of additional accounts, new accounts that we are not in today, which is right on strategy. Thanks for that. Perhaps then on just the distributor sales. So rebound in Q4 but still quite modest growth. So I think you touched upon this as well. But what can you elaborate a little bit on how you view the continued growth opportunities from Thermo in 2026 specifically?

Jan Wahlström
37:55 - 37:55

Guys.

Theis Kipling
37:56 - 39:21

Yeah. So if we take overall distributor channel performance, and then I'll come to the Thermo component in a second. But overall, going back 18 to 24 months. We have in various ways restructured the distributor channel, which was back in the day very reliant on pure PCR fragment analysis. Now we have added quite a number of new distributors for NGS, and those distributors usually are strong in either one of them. And that has been helping us. And I think we are a much stronger and more future-proof channel when it comes to the distribution business. And we're opening up gradually many new markets also, so that, excluding transplantation, it is going super strong and really well. Transplantation through the partnership with Thermo Fisher Scientific is equally strong, and as we have always said, we are very happy with the partnership, and they continue to deliver. And we recently got visibility to the accounts that they have onboarded over the past year. And we were all very, very pleased by seeing that. So there is commitment, as it has always been since the inception of the partnership. And I think we will see that that will be built upon here in the future as well. Did that answer Philip?

Phillip Wiberg
39:21 - 39:22

Okay.

Theis Kipling
39:22 - 39:22

Thanks.

Phillip Wiberg
39:22 - 39:47

Absolutely. Yes. Very good. Thanks. Perhaps I can just continue. So you're getting a little bit better visibility into this. But we still have the quarterly variations, and I suppose they will stick around into next year as well. And I know you don't want to give overall guidance on this, but could you provide some information regarding the quarterly variation that you expect in 2026? Is it like a similar pattern as in 2025.

Jan Wahlström
39:47 - 40:10

Or I can take that one. I think what we did say is that we will most likely see a similar pattern, but we believe that the lumpiness in that will even out more this year, and even more so in the future. But a similar pattern is the most probable one, as you've seen this year.

Phillip Wiberg
40:14 - 41:09

Okay. Very good. And then just last question. More of a general one on the growth going forward. So you've had quite high growth rate over several years now. But during that period, you've also had quite significant investments in the organization. And now you've pulled the brake a little bit. In 2025, you have a significant focus on profitability. And we have also seen the growth rate now coming down in 25. So profitability remains in focus. So, given that, could you talk a little bit about how this affects your possibilities to grow? Like, are there any opportunities that you feel right now that you have to not pursue, or any opportunities that should have been able to drive growth, but you're currently holding back due to these profitability targets.

Jan Wahlström
41:10 - 41:46

We still have a very clear growth focus, and I believe that we are still investing heavily into that growth. We are investing in our R&D department, as well as in our collaborations with companies like Illumina and other partnerships we establish. We continue to drive towards a high growth number going forward. And we are not happy with staying on a lower growth path, but we want to continue with a high growth rate. I don't know if you want to comment more on that, guys.

Theis Kipling
41:47 - 42:35

I would say two things. Going back to the fundamentals of the business, direct business is growing really well. I think you had growth in the mid-20s. I think that is pretty solid. And that's excluding transplantation. I think we, as we also shared in the earnings call back in 2024, the US will be what unlocks the next level of growth. And we're waiting for the MolDx approval, which is going along well. And you can also now follow the progress on the FDA program. And those are two very significant levers for fueling growth. But even without that, the underlying fundamentals of the business are still growing very well.

Phillip Wiberg
42:39 - 42:42

And we are not happy with staying on a lower growth path; instead, we want to continue with a higher growth rate. I'll stop there for now. I'll stop there for now.

Operator
42:50 - 42:54

The next question comes from Oscar Bergmann from Redeye. And we are not happy with staying on a lower growth path, but we want to continue with a higher growth rate.

Oscar Bergmann
42:56 - 43:17

Hi, guys. Congrats on a very strong report. It seems like the market sentiment is. Very strange at the moment. So not really recognized in the share price. I just have a few follow up questions. The first one being, if you can just give me a sentence or two on the prospects for Spain to impact sales during 2026.

Jan Wahlström
43:19 - 43:20

Guys.

Theis Kipling
43:20 - 44:09

For Spain, we can't give you any specific guidance, but I hope that you will see that we are making a very clearly defined play here. And we expect to have this not only for 2026, but for the many coming years to drive a lot of additional growth. And we are essentially replicating the way of working from Italy. It's also with Gina, who is the leader, and he was the guy building Italy. He's still heading up and overseeing the Spanish market. We're relying on the same back office team when it comes to achieving excellence in applying to tenders. So there's a lot of things that will benefit the overall growth and drive acceleration, specifically in Spain.

Jan Wahlström
44:12 - 44:25

I can add to that as well. Oscar, I can add to that comment as well, that Spain is one of the top five countries in market size in Europe, and it's about the same size as Italy on the total market size.

Oscar Bergmann
44:27 - 45:06

It's also with Jan, who is the leader, and he was the guy building Italy. Thanks. If I can just do a follow-up question on Thermo Fisher, I believe in Q2 you mentioned that you expected a more quarter-by-quarter revenue buildup, and perhaps even less lumpiness. But it seems like you are now emphasizing that we should expect lumpiness going forward. I'm just wondering if I have understood this correctly and if you have seen anything change from Q2 that now makes you expect a lumpiness for this collaboration.

Jan Wahlström
45:08 - 45:09

Do you want to take that?

Theis Kipling
45:10 - 45:33

Yeah. No, no, I mean, I think what we said, both myself and also Jan, is that there will be lumpiness, but it will be gradually reduced. This year and moving ahead. Right. So and I think we are also seeing that from my chair here. So I'm hopeful that the lumpiness will be gradually reduced.

Oscar Bergmann
45:35 - 45:44

It's also with Sabina, who is the leader, and she was the one building Italy. So what you're saying is that maybe we should expect smaller sales, or sorry, smaller orders in every quarter rather than every other quarter?

Theis Kipling
45:45 - 47:02

I think that's the outcome, right? Ideally, that is also the case. And I think that's also what Thermo Fisher will do. But to give you some context to the situation, they insist on keeping inventory on their own premises. They have two distribution warehouses, one in Europe and one in the US, so that they can ship and deliver orders overnight, essentially, as demand grows, obviously that inventory they keep will deplete faster. And that will trigger an increased number of orders to Devyser, which is why we are already seeing that lumpiness is definitely reducing as more and more customers are onboarded. And those that have been onboarded a year ago are now starting to finalize their internal validations and are reaching full clinical routine. So that's just the sequence of things here. But you will still see lumpiness moving forward. The question is when? When will that end? I cannot give you an answer. But. But it's a good sign that it is being reduced because it means more and more customers are repeating the repurchasing, which is what we want.

Oscar Bergmann
47:03 - 47:18

Okay. And then just a final question on my end, you're targeting to submit this supplementary data set to MolDx after the summer, but what review time should we then maybe expect after that, before a decision has been made?

Jan Wahlström
47:20 - 47:25

The review time that MolDx has. Correct me if I'm wrong, there is 60 days.

Theis Kipling
47:26 - 47:26

Correct.

Oscar Bergmann
47:26 - 47:33

Okay, great. So by then, it should be a fair assessment.

Jan Wahlström
47:37 - 47:39

Yes, that's a fair assessment.

Oscar Bergmann
47:42 - 47:43

Okay. The question is when?

Operator
47:52 - 47:56

The next question comes from Ludvig Lundgren from Nordea. The question is when?

Ludvig Lundgren
47:58 - 48:18

Yes. Hi. I just had a follow-up on the US. I think you previously highlighted that you are able to onboard transplant centers if they handle internal validation of the kits themselves. Like, have you seen any progress here. And do these types of customers already contribute to sales in the region?

Theis Kipling
48:21 - 49:01

Yeah, I can answer that one. Yes. That is correctly understood, and we are seeing some of those accounts gradually coming on board, which will also limit the lumpiness, right. As they get fully ramped. It is a longer validation process. But I think we have actually shared in the past that, through Thermo Fisher Scientific, we have quite some prominent institutions in the US that have and hold a lot of volume. So, we're supporting everything that we possibly can to make sure that they reach their clinical full potential at the earliest.

Ludvig Lundgren
49:04 - 49:12

Okay, but I assume these are quite low or only a small share of the total sales in Americas currently. Is that fair?

Theis Kipling
49:15 - 49:18

I'm not sure we can actually comment on that.

Ludvig Lundgren
49:19 - 49:22

Okay. Fair enough. Yeah. Thank you very much.

Operator
49:27 - 49:33

There are no more questions at this time. I hand the conference back to the speakers for any closing comments.

Jan Wahlström
49:35 - 49:43

So thanks again for everyone joining our call today. And, looking forward to the next time. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…